Abbott Laboratories Operating Income 2011-2025 | ABT
Abbott Laboratories annual/quarterly operating income history and growth rate from 2011 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Abbott Laboratories operating income for the quarter ending September 30, 2025 was $2.057B, a 10.65% increase year-over-year.
- Abbott Laboratories operating income for the twelve months ending September 30, 2025 was $7.713B, a 15.22% increase year-over-year.
- Abbott Laboratories annual operating income for 2024 was $6.825B, a 5.36% increase from 2023.
- Abbott Laboratories annual operating income for 2023 was $6.478B, a 22.53% decline from 2022.
- Abbott Laboratories annual operating income for 2022 was $8.362B, a 0.75% decline from 2021.
|
Abbott Laboratories Annual Operating Income (Millions of US $) |
|
|---|---|
| 2024 | $6,825 |
| 2023 | $6,478 |
| 2022 | $8,362 |
| 2021 | $8,425 |
| 2020 | $5,357 |
| 2019 | $4,532 |
| 2018 | $3,650 |
| 2017 | $1,564 |
| 2016 | $3,026 |
| 2015 | $2,867 |
| 2014 | $2,599 |
| 2013 | $2,133 |
| 2012 | $1,360 |
| 2011 | $1,629 |
| 2010 | $6,088 |
|
Abbott Laboratories Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2025-09-30 | $2,057 |
| 2025-06-30 | $2,052 |
| 2025-03-31 | $1,693 |
| 2024-12-31 | $1,911 |
| 2024-09-30 | $1,859 |
| 2024-06-30 | $1,669 |
| 2024-03-31 | $1,386 |
| 2023-12-31 | $1,780 |
| 2023-09-30 | $1,647 |
| 2023-06-30 | $1,542 |
| 2023-03-31 | $1,509 |
| 2022-12-31 | $1,304 |
| 2022-09-30 | $1,770 |
| 2022-06-30 | $2,376 |
| 2022-03-31 | $2,912 |
| 2021-12-31 | $2,378 |
| 2021-09-30 | $2,546 |
| 2021-06-30 | $1,392 |
| 2021-03-31 | $2,109 |
| 2020-12-31 | $2,432 |
| 2020-09-30 | $1,495 |
| 2020-06-30 | $672 |
| 2020-03-31 | $758 |
| 2019-12-31 | $1,389 |
| 2019-09-30 | $1,198 |
| 2019-06-30 | $1,206 |
| 2019-03-31 | $739 |
| 2018-12-31 | $1,165 |
| 2018-09-30 | $995 |
| 2018-06-30 | $882 |
| 2018-03-31 | $608 |
| 2017-12-31 | $651 |
| 2017-09-30 | $769 |
| 2017-06-30 | $386 |
| 2017-03-31 | $-242 |
| 2016-12-31 | $789 |
| 2016-09-30 | $897 |
| 2016-06-30 | $816 |
| 2016-03-31 | $524 |
| 2015-12-31 | $815 |
| 2015-09-30 | $713 |
| 2015-06-30 | $729 |
| 2015-03-31 | $610 |
| 2014-12-31 | $829 |
| 2014-09-30 | $728 |
| 2014-06-30 | $677 |
| 2014-03-31 | $365 |
| 2013-12-31 | $418 |
| 2013-09-30 | $473 |
| 2013-06-30 | $627 |
| 2013-03-31 | $615 |
| 2012-12-31 | $-23 |
| 2012-09-30 | $310 |
| 2012-06-30 | $564 |
| 2012-03-31 | $509 |
| 2011-12-31 | $2,082 |
| 2011-09-30 | $595 |
| 2011-06-30 | $1,773 |
| 2011-03-31 | $1,301 |
| 2010-12-31 | $1,830 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $224.767B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EssilorLuxottica (ESLOY) | France | $171.623B | 0.00 |
| Boston Scientific (BSX) | United States | $155.627B | 35.59 |
| Stryker (SYK) | United States | $142.805B | 28.35 |
| Medtronic (MDT) | Ireland | $123.317B | 17.39 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.676B | 0.00 |
| Agilent Technologies (A) | United States | $41.643B | 26.95 |
| ResMed (RMD) | United States | $36.793B | 25.47 |
| GE HealthCare Technologies (GEHC) | United States | $33.695B | 16.11 |
| Koninklijke Philips (PHG) | Netherlands | $27.848B | 18.19 |
| Insulet (PODD) | United States | $23.402B | 72.64 |
| Terumo (TRUMY) | Japan | $22.490B | 25.32 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.949B | 11.19 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.072B | 0.00 |
| Baxter (BAX) | United States | $9.613B | 7.76 |
| Sunny Optical Technology (SNPTF) | China | $9.361B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.548B | 30.74 |
| Demant (WILYY) | Denmark | $7.346B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $3.522B | 10.73 |
| Haemonetics (HAE) | United States | $3.460B | 15.40 |
| ICU Medical (ICUI) | United States | $3.420B | 21.71 |
| Envista Holdings (NVST) | United States | $3.270B | 18.76 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.120B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.885B | 13.16 |
| LeMaitre Vascular (LMAT) | United States | $2.034B | 40.93 |
| Perrigo (PRGO) | Ireland | $1.923B | 4.82 |
| Phibro Animal Health (PAHC) | United States | $1.812B | 18.10 |
| Curaleaf Holdings (CURLF) | Canada | $1.735B | 0.00 |
| AtriCure (ATRC) | United States | $1.577B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.507B | 9.69 |
| Neogen (NEOG) | United States | $1.384B | 26.54 |
| Green Thumb Industries (GTBIF) | United States | $1.379B | 60.46 |
| Kestra Medical Technologies (KMTS) | United States | $1.282B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.269B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.264B | 18.29 |
| BioLife Solutions (BLFS) | United States | $1.210B | 359.14 |
| InMode (INMD) | Israel | $0.904B | 10.21 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.831B | 0.00 |
| Valneva SE (VALN) | France | $0.794B | 0.00 |
| Surmodics (SRDX) | United States | $0.592B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.499B | 17.17 |
| Evolus (EOLS) | United States | $0.478B | 0.00 |
| CeriBell (CBLL) | United States | $0.463B | 0.00 |
| SNDL (SNDL) | Canada | $0.447B | 0.00 |
| Omeros (OMER) | United States | $0.427B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.427B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.381B | 0.00 |
| Cerus (CERS) | United States | $0.307B | 0.00 |
| Brainsway (BWAY) | Israel | $0.304B | 53.37 |
| Sanuwave Health (SNWV) | United States | $0.288B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.286B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.264B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.264B | 0.00 |
| High Tide (HITI) | Canada | $0.250B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.249B | 146.33 |
| Quanterix (QTRX) | United States | $0.249B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.244B | 19.42 |
| Owens & Minor (OMI) | United States | $0.227B | 2.27 |
| TriSalus Life Sciences (TLSI) | United States | $0.219B | 0.00 |
| Exagen (XGN) | United States | $0.212B | 0.00 |
| Organigram Global (OGI) | Canada | $0.207B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.191B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.180B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.180B | 15.85 |
| Sanara MedTech (SMTI) | United States | $0.175B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.173B | 21.33 |
| OraSure Technologies (OSUR) | United States | $0.164B | 0.00 |
| Apyx Medical (APYX) | United States | $0.156B | 0.00 |
| Biote (BTMD) | United States | $0.119B | 5.20 |
| Jushi Holdings (JUSHF) | United States | $0.106B | 0.00 |
| MacroGenics (MGNX) | United States | $0.101B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.098B | 0.00 |
| Fonar (FONR) | United States | $0.091B | 13.27 |
| Sharps Technology (STSS) | United States | $0.091B | 0.00 |
| Agape ATP (ATPC) | $0.069B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.055B | 23.27 |
| Nephros (NEPH) | United States | $0.047B | 34.00 |
| Cytosorbents (CTSO) | United States | $0.042B | 0.00 |
| Jin Medical (ZJYL) | China | $0.041B | 0.00 |
| Veru (VERU) | United States | $0.037B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Bonk (BNKK) | United States | $0.030B | 0.00 |
| United-Guardian (UG) | United States | $0.028B | 14.35 |
| Modular Medical (MODD) | United States | $0.027B | 0.00 |
| Zynex (ZYXI) | United States | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.010B | 0.00 |
| INLIF (INLF) | China | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | Canada | $0.001B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |